GRFS

Grifols S A

9.54

0.12+1.27%

After Hours: 9.54 0.00 0.00%19:36 02/04 EST

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE9.42/9.42

TODAY RANGE9.41-9.60

VOL419.55K

MARKET CAP6.56B

52 WEEK RANGE6.09-10.96

AVG VOL (3M)523.67K

% TURNOVER0.06%

TURNOVER--

P/E (TTM)14.87

% RANGE2.02%

EPS(TTM)0.6416

P/E(FORWARD)12.05

P/B1.066

BVPS8.95

DIVIDEND0.1758

P/S0.8650

BETA--

DIV YIELD1.84%

FREE FLOAT MKT CAP6.56B

SHARES OUTSTANDING687.55M

NEXT EARNINGS02/24-03/02

FREE FLOAT687.55M

LOT SIZE1

EX-DATE08/12/2025

News

Press Releases

Financial Reports

Profile

Seeking Alpha·01/27 02:15
White Falcon: Q4 2025 Portfolio Positions
Reuters·01/12 13:16
Rigel Pharmaceuticals prelim Q4 revenue beats estimates
TipRanks·01/08 20:47
Grifols Adjusts Board Secretariat Roles Effective January 1, 2026
Reuters·01/08 20:17
Grifols Names Laura de la Cruz Galán as Board Secretary and Núria Martín Barnés as Vice-secretary
TipRanks·01/06 18:40
Grifols price target lowered to EUR 13.50 from EUR 15 at Barclays
Seeking Alpha·12/28/2025 14:10
Grifols: Solid Q3 Execution, But Cash Conversion And 2026 Risks Keep Us Neutral
Reuters·12/19/2025 11:02
Biotest AG and Grifols Receive FDA Approval for Fesilty Fibrinogen Therapy
Reuters·12/19/2025 11:01
Grifols Secures FDA Approval for FESILTY Fibrinogen Concentrate for Congenital Fibrinogen Deficiency
Reuters·12/19/2025 11:01
GRIFOLS - RECEIVES US FDA APPROVAL FOR NEW FIBRINOGEN CONCENTRATE, FESILTYTM (FIBRINOGEN, HUMAN-CHMT)
Reuters·12/17/2025 07:35
Grifols Upgraded to ‘BB-’ by S&P Global Ratings
TipRanks·12/16/2025 14:57
Grifols Achieves EMA Certification for Egyptian Plasma Operations
Reuters·12/16/2025 07:38
Grifols Gains EMA Approval for Entire Plasma Value Chain in Egypt
Dow Jones·12/09/2025 12:23
Correction to Grifols Price Target Headline
Seeking Alpha·12/08/2025 17:02
Grifols: Positive/Neutral Scenario Posits An Upside
Dow Jones·12/08/2025 16:17
Grifols Price Target Cut to $10.00/Share From $10.30 by JP Morgan

Same Industry

Name/Symbol

Change%

Price

Grifols S A

GRFS

+1.27%

9.54

McKesson

MCK

-3.42%

822.00

Biogen Inc

BIIB

+4.92%

185.45

Amgen Inc

AMGN

+8.15%

366.20

Shire

SHPG

179.20

Bristol-Myers Squibb Company Celegne Contingent Value Rights

CELG-RT

+26.36%

0.0949

Lilly Eli & Co

LLY

+10.33%

Celgene

CELG

108.24

Therapeuticsmd Inc

TXMD

-3.43%

2.25

Johnson & Johnson

JNJ

+0.59%

234.47

Abbvie Inc

ABBV

-3.79%

217.11

Zoetis Inc

ZTS

+3.50%

126.70

Gilead Sciences Inc

GILD

+2.06%

146.23

Novo-Nordisk A/S

NVO

-6.18%

47.19

Bristol-Myers Squibb Co

BMY

+2.91%

57.62

Alexion Pharms

ALXN

+1.70%

182.50

Pfizer

PFE

+3.92%

26.78

Sanofi FR

SNY

+1.24%

48.08

Sanofi FR

GCVRZ

0.00%

0.8711

Novartis

NVS

+2.04%

152.91

Dr Reddys Labs

RDY

+1.38%

14.00

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.